The OncoArray Consortium, an endeavor involving 550 researchers from 6 continents, identified new target genes that may allow for better definition of the pathways and mechanisms underlying breast cancer susceptibility.
In this interview with Mary Daly, MD, PhD, she gives an overview of multigene panel testing for breast cancer, and how they can be used by clinicians to interpret risk and treat accordingly.
A new study suggests that the protein NFS1 provides a central protection for cancer cells against oxygen and that it may be possible to leverage this discovery into a new lung cancer treatment.
Researchers report on the development of a blood-based assay that could potentially provide an earlier warning of small cell lung cancer relapse by improving diagnostic lead-time compared with CT scan.
Researchers analyzed samples from 1,122 patients with advanced-stage NSCLC and discovered that 92.9% of tumors from harbored multiple changes in cancer-related genes in addition to the EGFR driver mutation.
In a recent study, more than half of patients with rare cancers who had their genomic markers analyzed were able to receive targeted therapy that resulted in a clinical benefit.
Poizotinib, once abandoned as a general EGFR inhibitor, recently demonstrated tumor shrinkage in patients with an EGFR exon 20 insertion mutation.
An investigational therapy using modified poliovirus to attack cancer appears to unleash the body’s own capacity to fight malignancies by activating a newly identified inflammatory process.
Researchers have discovered that androgen signaling can either stimulate or suppress tumor cell movement and invasion to different locations in the body in patients who have renal cell carcinoma.
In this podcast interview, Dr. William Wierda discusses the role of venetoclax in treating patients with chronic lymphocytic leukemia, particularly in light of recent trial results.
The FDA approved alectinib as first-line therapy for ALK-positive non-small cell lung cancer based on results of the ALEX study, which showed significant improved PFS compared with crizotinib.
Data from three independent cohorts suggest that high EZH2 expression may mean a higher risk of death for patients with clear cell renal cell carcinoma.
Researchers have found that melanoma patients may benefit from a holiday from MAPK inhibitors while alternative therapies stave off emergence of resistant melanoma clones.
Data presented at the recent World Conference on Lung Cancer show that pembrolizumab improves overall survival in patients with metastatic non-small cell lung cancer whose tumors express high levels of PD-L1.
Tumor Infiltrating Lymphocytes May be Predictive in African-American Women with Triple-Negative Breast Cancer
For African-American women with triple-negative breast cancer, high levels of tumor infiltrating lymphocytes may mean a better prognosis.